米氮平与氟西汀治疗抑郁症的对照研究

目的比较米氮平与氟西汀治疗抑郁症的疗效和安全性。方法将70例抑郁症患者随机分为米氮平组(35例)和氟西汀组(35例)。进行为期6周的治疗观察。用汉密顿抑郁量表评定其疗效。采用副反应量表、体验及实验室检查评价安全性,分别在治疗0、1、2、4、6周末评定疗效和不良反应。结果①两组治疗后HAMD评分均明显低于治疗前,差异有统计学意义(p<0.001)。②治疗后1周末,米氮平组HAMD量表总分、焦虑/躯体化因子、阻滞因子、睡眠障碍因子评分均较氟西汀组低,且有统计学意义(p<0.05)。研究结束时,上述指标的组间差异没有统计学意义。③经过6周的治疗,有效率和治愈率米氮平分别为82.9%和68.6%,氟西汀组分别为80%和65.7%,差异没有统计学意义(p>0.05)。④安全性评定:两组比较差异无统计学意义(p>0.05)。结论米氮平治疗抑郁症有效而安全,且起效时间早于氟西汀。

MIRTAZAPINE AND FLUOXETINE IN THE TREATMENT OF DEPRESSION.

ObjectiveTo evaluate the efficacy and safety of mirtazapine and fluoxetine in the treatment of depression.Method 70 patients with depression were randomly treated with mirtazapine or fluexetine for 6 weeks(each group 35 patients).Evaluate the efficacy with HAMD.Measured the safety with TESS,physical and laboratory examinations at the baseline,the first weekend,the second weekend,the forth weekend and the sixth weekend.Result ①The scores of HAMD for both groups were obviously decreased after treatment(p<0.001).②HAMD,the scores of anxiety,depression in mirtazapine group were statistically lower than those in fluoxetine group at the first weekend(p<0.05).The differences became insignificant at the end of the trial.③The response rates and cure rateof mirtazapine and fluoxetine were 82.9%,68.6% and 80%,65.7%respectively.④Safety measures were not significantly different between two groups(p>0.05).Conclusion Mirtazapine is safe and effective in the treatment of depression,and its effect appears earlier than that of fluoxetine.